Angiotensin receptors are a class of G protein-coupled receptors with angiotensin II as their ligands. They are important in the renin-angiotensin system: they are responsible for the signal transduction of the vasoconstricting stimulus of the main effector hormone, angiotensin II. The AT1 and AT2 receptors have a similar affinity for angiotensin II, which is their main ligand. The AT1 receptor is the best elucidated angiotensin receptor. AT2 receptors are more plentiful in the fetus and neonate. Other poorly characterized subtypes include the AT3 and AT4 receptors.
### Angiotensin Receptor Inhibitors & Modulators

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Bioactivity</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>A 779</td>
<td>HY-P0216</td>
<td>A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an Ang1-7 receptor distinct from the classical AngII. Sequence: Asp-Arg-Val-Tyr-Ile-His-d-Ala.</td>
<td>98.0%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 1 mg, 5 mg</td>
</tr>
<tr>
<td>A81988</td>
<td>HY-U00188</td>
<td>A81988 is a potent, competitive, non-peptidic antagonist of angiotensin AT₁ receptors.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg, 10 mg, 20 mg</td>
</tr>
<tr>
<td>Angiotensin 1-7 (Angiotensin-(1-7); Ang-(1-7))</td>
<td>HY-12403</td>
<td>Angiotensin (1-7) inhibits purified canine angiotensin converting enzyme (ACE) activity with an IC₅₀ of 0.65 μM.</td>
<td>99.61%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg</td>
</tr>
<tr>
<td>Angiotensin II (3-8), human</td>
<td>HY-P1515</td>
<td>Angiotensin II (3-8), human is a less effective agonist at the angiotensin AT₁ receptor.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 10 mg, 25 mg</td>
</tr>
<tr>
<td>Angiotensin II human (Angiotensin II; Hypertensin II; Ang II; DRVYIHPF)</td>
<td>HY-13948</td>
<td>Angiotensin II human is a vasoconstrictor that acts on the AT₁ and the AT₂ receptor.</td>
<td>99.83%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in Water, 10 mg, 50 mg</td>
</tr>
<tr>
<td>Angiotensin III, human, mouse</td>
<td>HY-P1540</td>
<td>Angiotensin III, human, mouse is a heptapeptide, acts as an endogenous angiotensin type 2 receptor (AT₂R) agonist, with IC₅₀ of 0.648 nM and 21.1 nM for AT₁R and AT₂R, respectively.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>AVE 0991</td>
<td>HY-15778</td>
<td>AVE 0991 is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [¹²⁵I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC₅₀ of 21±35 nM.</td>
<td>99.16%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>AVE 0991 sodium salt</td>
<td>HY-15778A</td>
<td>AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [¹²⁵I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC₅₀ of 21±35 nM.</td>
<td>99.32%</td>
<td>No Development Reported</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>
### Azilsartan (TAK-536)
**Cat. No.: HY-14914**

**Bioactivity:** Azilsartan(TAK-536) is a specific and potent angiotensin II type 1 receptor antagonist with IC50 of 2.6 nM.

**Purity:** 99.58%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 100 mg

### Azilsartan D5 (TAK-536 D5)
**Cat. No.: HY-14914S**

**Bioactivity:** Azilsartan D5 is the deuterium labeled Azilsartan(TAK-536), which is a specific and potent angiotensin II type 1 receptor antagonist.

**Purity:** 98.0%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg

### Azilsartan medoxomil (TAK-491)
**Cat. No.: HY-14736**

**Bioactivity:** Azilsartan medoxomil(TAK-491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.

**Purity:** > 98%

**Clinical Data:** Launched

**Size:** 5 mg, 10 mg, 50 mg

### Azilsartan medoxomil monopotassium (Azilsartan kamedoxomil; TAK 491 monopotassium)
**Cat. No.: HY-17458**

**Bioactivity:** Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.

**Purity:** 95.35%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

### BIBS 39
**Cat. No.: HY-19732**

**Bioactivity:** BIBS 39 is a new nonpeptide angiotensin II (ATII) receptor antagonist.

**Purity:** 99.36%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg

### C-Type Natriuretic Peptide (CNP) (1-22), human
**Cat. No.: HY-P1237**

**Bioactivity:** C-Type Natriuretic Peptide (CNP) (1-22), human is the 1-22 fragment of C-Type Natriuretic Peptide. C-type natriuretic peptide is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular tone.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 500u g, 1 mg, 5 mg

### Candesartan (CV 11974)
**Cat. No.: HY-80205**

**Bioactivity:** Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.

**Purity:** 96.20%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg

### Candesartan Cilexetil (TCV-116)
**Cat. No.: HY-17505**

**Bioactivity:** Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.

**Purity:** 98.0%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 500 mg, 1 g

### Candesartan D4 (CV-11974 D4)
**Cat. No.: HY-80205S**

**Bioactivity:** Candesartan D4 is the deuterium labeled Candesartan, which is an angiotensin II receptor antagonist.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

### CGP-42112 (CGP42112A)
**Cat. No.: HY-12405**

**Bioactivity:** CGP-42112(CGP-42112A) is a potent Angiotensins-II subtype 2 receptor(AT2 R) agonist. IC50 value: Target: AT2 R agonist in vitro: CGP42112 (> ==1 nM) significantly inhibited cGMP production from the basal value. CGP42112 (> ==1 nM) significantly inhibited TH-enzyme activity from the basal...

**Purity:** 98.82%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg
### CGP48369
**Bioactivity:** CGP48369 is a nonpeptidic angiotensin II receptor antagonist, used for anti-hypertensive research.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg, 10 mg, 20 mg |

### Elisartan (HN 65021)
**Bioactivity:** Elisartan is an orally active non-peptide pro-drug of angiotensin-II AT1 receptor antagonist HN-12206, and shows anti-hypertension activities.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg, 10 mg, 20 mg |

### EMA401 (Olodanrigan)
**Bioactivity:** EMA401, a highly selective AT2R antagonist, inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons. target: AT2R In vivo: AngII induces p38, p42/p44 mitogen activated protein kinase (MAPK),...

| Purity: | 98.52% |
| Clinical Data: | Phase 2 |
| Size: | 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg |

### Eprosartan mesylate (SKF-108566J)
**Bioactivity:** Eprosartan is a nonpeptide angiotensin II receptor antagonist with IC50 of 9.2 and 3.9 nM in rat and human adrenal cortical membranes, respectively.

| Purity: | 99.79% |
| Clinical Data: | Launched |
| Size: | 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg |

### Fimasartan (BR-A-657)
**Bioactivity:** Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure.

| Purity: | 98.77% |
| Clinical Data: | Launched |
| Size: | 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

### Irbesartan (SR-47436; BMS-186295)
**Bioactivity:** Irbesartan is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.

| Purity: | 99.79% |
| Clinical Data: | Launched |
| Size: | 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg |

### Irbesartan D4 (SR-47436 D4; BMS-186295 D4)
**Bioactivity:** Irbesartan D4 is the deuterium labeled Irbesartan, which is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg |

### L-159282 (MK 996)
**Bioactivity:** L-159282 is a highly potent, orally active, nonpeptide angiotensin II receptor antagonist, with anti-hypertensive activity.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg, 10 mg, 20 mg |

### L162389
**Bioactivity:** L162389 is a potent antagonist of angiotensin AT1 receptor with Ki of 28 nM.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg, 10 mg, 20 mg |

### L162441
**Bioactivity:** L162441 is an Angiotensin type 1 receptor antagonist.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg, 10 mg, 20 mg |
**LCZ696**
(Valtsartan/sacubitril)
Cat. No.: HY-18204A

**Bioactivity:** LCZ696 is a dual angiotensin II receptor and nephrilysin inhibitor.

**Purity:** 99.96%
**Clinical Data:** Launched
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg

---

**Losartan**
(DuP-753)
Cat. No.: HY-17512

**Bioactivity:** Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC<sub>50</sub> of 20 nM.

**Purity:** 99.24%
**Clinical Data:** Launched
**Size:** 10 mM x 1 mL in DMSO, 1 g, 5 g

---

**Losartan D4**
(DuP-753 D4)
Cat. No.: HY-17512S

**Bioactivity:** Losartan D4 is the deuterium labeled Losartan. Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC<sub>50</sub> of 20 nM.

**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

---

**Losartan potassium**
(DuP-753 potassium)
Cat. No.: HY-17512A

**Bioactivity:** Losartan potassium is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC<sub>50</sub> of 20 nM.

**Purity:** 99.91%
**Clinical Data:** Launched
**Size:** 10 mM x 1 mL in DMSO, 1 g, 5 g

---

**LY285434**
Cat. No.: HY-U00202

**Bioactivity:** LY285434 is a suitable angiotensin II receptor antagonist.

**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg, 10 mg

---

**Olmesartan**
(RNH 6270, CS 088)
Cat. No.: HY-17004

**Bioactivity:** Olmesartan is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure.

**Purity:** 99.01%
**Clinical Data:** Launched
**Size:** 10 mM x 1 mL in DMSO, 100 mg, 500 mg

---

**Olmesartan D4**
(RNH-6270 D4, CS-088 D4)
Cat. No.: HY-17004S

**Bioactivity:** Olmesartan D4 is the deuterium labeled Olmesartan. Olmesartan is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure.

**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

---

**Olmesartan medoxomil**
(CS 866)
Cat. No.: HY-17005

**Bioactivity:** Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC<sub>50</sub> of 66.2 μM.

**Purity:** 99.03%
**Clinical Data:** Launched
**Size:** 10 mM x 1 mL in DMSO, 10 mg, 50 mg, 100 mg

---

**PD 123319**
((S)-(+-)PD 123319)
Cat. No.: HY-10259

**Bioactivity:** PD 123319 (diprifluoroacetate) is a potent, selective AT2 angiotensin II receptor antagonist with IC<sub>50</sub> of 34 nM.

**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 50 mg
### Bioactivity:

**PD 123319 ditrifluoroacetate**
*Cat. No.: HY-10259A*

- **Bioactivity:** PD 123319 (ditrifluoroacetate) is a potent, selective AT2 receptor antagonist with IC50 of 34 nM.
- **Purity:** 99.76%
- **Clinical Data:** No Development Reported
- **Size:** 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg

**Pratosartan**
*Cat. No.: HY-101574*

- **Bioactivity:** Pratosartan is a selective angiotensin II receptor antagonist.
- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg, 10 mg, 20 mg

**SL910102**
*Cat. No.: HY-100292*

- **Bioactivity:** SL910102 is a nonpeptide AT1 receptor antagonist.
- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg, 10 mg

**Sparsetan**
*(RE-021; BMS-346567; PS433540; DARA-a)*
*Cat. No.: HY-17621*

- **Bioactivity:** Sparsetan (RE-021; BMS-346567; PS433540; DARA-a) is a highly potent dual angiotensin II and endothelin A receptor antagonist with IC50 of 0.8 and 9.3 nM, respectively.
- **Purity:** 99.08%
- **Clinical Data:** Phase 2
- **Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**Tasosartan**
*(WAY-ANA 756)*
*Cat. No.: HY-A0250*

- **Bioactivity:** Tasosartan is a long-acting angiotensin II (AngII) receptor antagonist.
- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 5 mg, 10 mg

**Telmisartan**
*(BBR 277)*
*Cat. No.: HY-13955*

- **Bioactivity:** Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
- **Purity:** 99.96%
- **Clinical Data:** Launched
- **Size:** 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g

**Tranilast**
*(MK 341; SB 252218)*
*Cat. No.: HY-80195*

- **Bioactivity:** Tranilast is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.
- **Purity:** 99.60%
- **Clinical Data:** Launched
- **Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg

**Tranilast Sodium**
*(Sodium Tranilast; MK 341 Sodium; SB 252218 Sodium)*
*Cat. No.: HY-80195A*

- **Bioactivity:** Tranilast is an antiallergic agent. Target: Angiotensin Receptor Tranilast has been approved in Japan and South Korea, since 1982, for the treatment of bronchial asthma, with indications for keloids and hypertrophic scar added in 1993. Tranilast is also used to treat asthma, autoimmune diseases,...
- **Purity:** >98%
- **Clinical Data:** Launched
- **Size:** 10 mg, 50 mg

**Tranilast trans- (trans-Tranilast)**
*Cat. No.: HY-18706*

- **Bioactivity:** Trans-Tranilast is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.
- **Purity:** 99.66%
- **Clinical Data:** No Development Reported
- **Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg

**Valsartan**
*(CGP 48933)*
*Cat. No.: HY-18204*

- **Bioactivity:** Valsartan (CGP-48933) is an angiotensin II receptor antagonist for treatment of high blood pressure and heart failure.
- **Purity:** 99.35%
- **Clinical Data:** Launched
- **Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg
| **Valsartan D9**  
(CGP-48933 D9) | Cat. No.: HY-182045 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Valsartan D9 (CGP-48933 D9) is deuterium labeled valsartan. Valsartan is an <strong>angiotensin II</strong> receptor antagonist for treatment of high blood pressure and heart failure.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>1 mg, 5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ZD 7155(hydrochloride)</strong></th>
<th>Cat. No.: HY-102093</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>ZD 7155 hydrochloride is an angiotensin II receptor type 1 (<strong>AT1 receptor</strong>) antagonist.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>250 mg, 500 mg</td>
</tr>
</tbody>
</table>

| **[Sar1, Ile8]-Angiotensin II**  
(Angiotensin II, Angiotensin 2) | Cat. No.: HY-P1564 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>[Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10 mg, 50 mg</td>
</tr>
</tbody>
</table>